David J. Van Wazer
A5033505662- HIV Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- HIV/AIDS drug development and treatment
- Immune Cell Function and Interaction
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Influenza Virus Research Studies
- Herpesvirus Infections and Treatments
- Bacteriophages and microbial interactions
National Institute of Allergy and Infectious Diseases
2023-2025
National Institutes of Health
2023-2025
The conserved influenza hemagglutinin stem, which is a target of cross-neutralizing antibodies, now used in vaccine strategies focused on protecting against pandemics. Antibody responses to group 1 stem have been extensively characterized, but little known about 2. Here, we characterized the stem-specific repertoire individuals vaccinated with one three 2 subtypes (H3, H7, or H10). Epitope mapping revealed two epitope supersites stem. Antibodies targeting central were broadly cross-reactive,...
Elicitation of antibodies that neutralize the tier-2 neutralization-resistant isolates typify HIV-1 transmission has been a long-sought goal. Success with prefusion-stabilized envelope trimers eliciting autologous neutralizing reported in multiple vaccine-test species, though not humans. To investigate elicitation humans, here, we analyze B cells from phase I clinical trial "DS-SOSIP"-stabilized trimer strain BG505, identifying two antibodies, N751-2C06.01 and N751-2C09.01 (named for...
Soluble HIV-1-envelope (Env) trimers elicit immune responses that target their solvent-exposed protein bases, the result of removing these from native membrane-bound context. To assess whether glycosylation could limit base responses, we introduced sequons encoding potential N-linked sites (PNGSs) into base-proximal regions. Expression and antigenic analyses indicated bearing six-introduced PNGSs to have reduced recognition. Cryo-EM analysis revealed with be prone disassembly PNGS...
Studies suggest that the protection against SIV/simian-human immunodeficiency virus (SHIV) acquisition afforded by SIV/HIV V1 deletion-containing envelope immunogens, delivered DNA/ALVAC vaccine platform, requires multiple innate and adaptive host responses. Anti-inflammatory macrophages tolerogenic dendritic cells (DC-10), together with CD14 + efferocytes, are consistently found to correlate a vaccine-induced decrease in risk of SIV/SHIV acquisition.